Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events

Human Gene Therapy

Volumn 21, Issue 9, 2010, Pages 1039-1042

  Büning, Hildegard ^a   Uckert, Wolfgang ^b   Cichutek, Klaus ^c   Hawkins, Robert E ^d   Abken, Hinrich ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c PAUL EHRLICH INSTITUT   (Germany)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; CANCER CELL; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; HUMAN; METASTASIS; NOTE; T LYMPHOCYTE;

EID: 77957854950     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.131     Document Type: Note

References (26)

1. + T cells for use in the adoptive immunotherapy of cancer. Gene Ther. 16, 596-604.
2. Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., and Sadelain, M. (2010a). Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 18, 666-668.
3. Brentjens, R., Riviere, I., Frattini, M., Wang, Y., Taylor, C., Olszewska, M. Borquez-Ojeda, O., Bartido, S., Stefanski, J., Yeh, R., and Sadelain, M. (2010b). Marked regression of ade-nopathy following infusion of autologous T cells genetically targeted to the CD19 antigen in a patient with bulky CLL. Abstract presented at the 13th Annual Meeting of the American Society of Gene and Cell Therapy, May 17-22, 2010, Washington, D.C.
4. Brentjens, R.J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintás-Cardama, A., Larson, S.M., and Sadelain, M. (2007). Genetically targeted T cell eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13, 5426-5435.
5. Carpenito, C., Milone, M.C., Hassan, R., Simonet, J.C., Lakhal, M., Suhoski, M.M., Varela-Rohena, A., Haines, K.M., Heitjan, D.F., Albelda, S.M., Carroll, R.G., Riley, J.L., Pastan, I., and June, C.H. (2009). Control of large, established tumor xeno-grafts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U.S.A. 106, 3360-3365.
6. Chmielewski, M., Hombach, A., Heuser, C., Adams, G.P., and Abken, H. (2004). T cell activation by antibody-like im-munoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J. Immunol. 173, 7647-7653.
7. Ciceri, F., Bonini, C., Stanghellini, M.T., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., Pescarollo, A., Servida, P., Magnani, Z., Perna, S.K., Valtolina, V., Crippa, F., Callegaro, L., Spoldi, E., Crocchiolo, R., Fleischhauer, K., Ponzoni, M., Vago, L., Rossini, S., Santoro, A., Todisco, E., Apperley, J., Olavarria, E., Slavin, S., Weissinger, E.M., Ganser, A., Stadler, M., Yannaki, E., Fassas, A., Anagnostopoulos, A., Bregni, M., Stampino, C.G., Bruzzi, P., and Bordignon, C. (2009). Infusion of suicide-gene-engineered donor lymphocytes after family haploiden-tical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): A non-randomised phase I-II study. Lancet Oncol. 10, 489-500.
8. Cooper, L.J., Al-Kadhimi, Z., Serrano, L.M., Pfeiffer, T., Olivares, S., Castro, A., Chang, W.C., Gonzalez, S., Smith, D., Forman, S.J., and Jensen, M.C. (2005). Enhanced anti-lymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modifiedtopresent influenza MP1. Blood 105, 1622-1631.
9. de Witte, M.A., Jorritsma, A., Swart, E., Straathof, K.C., de Punder, K., Haanen, J.B., Rooney, C.M., and Schumacher, T.N. (2008). An inducible caspase-9 safety switch can halt cell therapy-induced autoimmune disease. J. Immunol. 180, 6365-6373.
10. Dudley, M.E., Wunderlich, J.R., Yang, J.C., Sherry, R.M., Topalian, S.L., Restifo, N.P., Royal, R.E., Kammula, U., White, D.E., Mavroukakis, S.A., Rogers, L.J., Gracia, G.J., Jones, S.A., Mangiameli, D.P., Pelletier, M.M., Gea-Banacloche, J., Robinson, M.R., Berman, D.M., Filie, A.C., Abati, A., and Rosenberg, S.A. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346-2357.
11. Dudley, M.E., Yang, J.C., Sherry, R., Hughes, M.S., Royal, R., Kammula, U., Robbins, P.F., Huang, J., Citrin, D.E., Leitman, S.F., Wunderlich, J., Restifo, N.P., Thomasian, A., Downey, S.G., Smith, F.O., Klapper, J., Morton, K., Laurencot, C., White, D.E., and Rosenberg, S.A. (2008). Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239.
12. Eshhar, Z. (2008). The T-body approach: Redirecting T cells with antibody specificity. Handb. Exp. Pharmacol. 181, 329-342.
13. Hombach, A., Hombach, A.A., and Abken, H. (2010). Adoptive immunotherapy with genetically engineered T cells: Modification of the IgG1 Fc "spacer" domain in the extracellular moiety of chimeric antigen receptors avoids "off-target" activation and unintended initiation of an innate immune response. Gene Ther. 2010 Jun 17. [Epub ahead of print] doi: 10.1038/gt.2010.91
14. Hoyos, V., Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H.E., Rooney, C.M., Brenner, M.K., and Dotti, G. (2010). Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24, 1160-1170.
15. Johnson, L.A., Morgan, R.A., Dudley, M.E., Cassard, L., Yang, J.C., Hughes, M.S., Kammula, U.S., Royal, R.E., Sherry, R.M., Wunderlich, J.R., Lee, C.C., Restifo, N.P., Schwarz, S.L., Cog-dill, A.P., Bishop, R.J., Kim, H., Brewer, C.C., Rudy, S.F., Vanwaes, C., Davis, J.L., Mathur, A., Ripley, R.T., Nathan, D.A., Laurencot, C.M., and Rosenberg, S.A. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546.
16. Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., White, D.E., Wunderlich, J.R., Cane-vari, S., Rogers-Freezer, L., Chen, C.C., Yang, J.C., Rosenberg, S.A., and Hwu, P. (2006). A phase I study on adoptive im-munotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115.
17. Kieback, E., Charo, J., Sommermeyer, D., Blankenstein, T., and Uckert, W. (2008). A safeguard eliminates T cell receptor gene modified autoreactive T cells after adoptive transfer. Proc. Natl. Acad. Sci. U.S.A. 105, 623-628.
18. Lamers, C.H., Sleijfer, S., Vulto, A.G., Kruit, W.H., Kliffen, M., Debets, R., Gratama, J.W., Stoter, G., and Oosterwijk, E. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhy-drase IX: First clinical experience. J. Clin. Oncol. 24, e20-e22.
19. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., and Rosenberg, S.A. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851.
20. Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., Huls, M.H., Liu, E., Gee, A.P., Mei, Z., Yvon, E., Weiss, H.L., Liu, H., Rooney, C.M., Heslop, H.E., and Brenner, M.K. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264-1270.
21. Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A., Brunner, M.D., and Panoskaltsis, N. (2006). Cyto-kine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028.
22. Tey, S.K., Dotti, G., Rooney, C.M., Heslop, H.E., and Brenner, M.K. (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol. Blood Marrow Transplant. 13, 913-924.
23. Till, B.G., Jensen, M.C., Wang, J., Chen, E.Y., Wood, B.L., Greisman, H.A., Qian, X., James, S.E., Raubitschek, A., For-man, S.J., Gopal, A.K., Pagel, J.M., Lindgren, C.G., Greenberg, P.D., Riddell, S.R., and Press, O.W. (2008). Adoptive immu-notherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271.
24. Uckert, W., Kammertöns, T., Haack, K., Qin, Z., Gebert, J., Schendel, D.J., and Blankenstein, T. (1998). Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum. Gene Ther. 9, 855-865.
25. Vera, J.F., Brenner, M.K., and Dotti, G. (2009). Immunotherapy of human cancers using gene modified T lymphocytes. Curr. Gene Ther. 9, 396-408.
26. Zhao, Y., Wang, Q.J., Yang, S., Kochenderfer, J.N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S.A., and Morgan, R.A. (2009). A Herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563-5574.